JW (Cayman) Therapeutics Co. Ltd. (02126) published its monthly return for the period ended 30 November 2025, confirming that its authorized share capital remains at 5,000,000,000 ordinary shares with a par value of USD 0.00001, amounting to a total of USD 50,000. No changes in authorized or issued share capital were reported during the month, with the total issued shares staying at 416,473,250 and no treasury shares recorded.

According to the monthly return, no new shares were issued under the company’s pre-IPO or post-IPO incentivization schemes. Multiple share option grants remain outstanding, though none resulted in additional share issuance for the period. The restricted share unit scheme shows 1,195,666 shares that may be issued or transferred out of treasury in the future, with no activity reported this month. The company confirmed compliance with all relevant regulatory requirements and maintained consistent share capital and treasury positions throughout November 2025.